Systemic sclerosis & Raynaud's
Autoantibodies directed against the angiotensin II type 1 receptor and the endothelin-1 type A receptor in patients with systemic sclerosis
Authors' conclusion
Previously described associations with disease manifestations and all-cause mortality could not be confirmed in our cohorts.
Study context
- Population
- Systemic sclerosis (SSc) patients (Leiden and Radboud cohorts), with primary RP, RA and healthy controls
- Participants
- 279 / 42 / 24 / 20 / 310
- Exposure
- SSc vs primary RP, RA and healthy controls
- SScn = 279
- Primary RPn = 42
- RAn = 24
- Healthy controlsn = 20reference
- Radboud SScn = 310
- Outcome
- Anti-AT1R and anti-ETAR AAb levels measured by ELISA and their associations with disease manifestations and all-cause mortality
Methodological detailsindependent validation cohort
- Independent validation cohort
Main finding
As reported in the abstract
Anti-AT1R and anti-ETAR AAb levels
- Applicability of autoantibodies (AAbs) against AT1R and ETAR detected by ELISA in the sera of all groups tested
- No associations between anti-AT1R or anti-ETAR AAbs and disease manifestations or all-cause mortality
- SSc vs pooled non-SSc: P = 0.043
Observational data: associations, not effects.
Further findings
Anti-ETAR AAb levels by disease manifestation (Radboud cohort)
- Higher median anti-ETAR AAb levels in diffuse cutaneous SSc
- P = 0.001
- Higher median anti-ETAR AAb levels in ILD
- P = 0.007
AAb levels in patients who died during follow-up (Radboud cohort)
- Lower anti-AT1R AAb levels
- P = 0.005
- Lower anti-ETAR AAb levels
- P = 0.020
Original publication
Autoantibodies directed against the angiotensin II type 1 receptor and the endothelin-1 type A receptor in patients with systemic sclerosis. RMD Open. Published 15 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →